ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.

Also called NCT01067820

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 324 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01067820
Other papers using this trial's data
  • Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016-02 DOI, PubMed 26385396

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Argentina, Belgium, Brazil, Hungary, Netherlands, Poland, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01067820. Randomized; triple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation
Acronym
ASSURE I
Intervention (Drug)
RVX000222
Intervention (Drug)
Placebo RVX000222
Lead sponsor
Resverlogix Corp (class: industry)
Collaborator
The Cleveland Clinic (class: other)

Record details

Record id
cardio:ct-nct01067820
Content hash
649aa73d68855a3b481c19f4707da3951e61a56dcd1f0efa4e16976d64b7529d